HK1198827A1 - 抑制劑及其用途 - Google Patents
抑制劑及其用途Info
- Publication number
- HK1198827A1 HK1198827A1 HK14112274.6A HK14112274A HK1198827A1 HK 1198827 A1 HK1198827 A1 HK 1198827A1 HK 14112274 A HK14112274 A HK 14112274A HK 1198827 A1 HK1198827 A1 HK 1198827A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- dyrk1
- inhibitors
- dyrk1 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11178190 | 2011-08-19 | ||
| PCT/EP2012/066151 WO2013026806A1 (en) | 2011-08-19 | 2012-08-17 | Dyrk1 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198827A1 true HK1198827A1 (zh) | 2015-06-12 |
Family
ID=46704656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14112274.6A HK1198827A1 (zh) | 2011-08-19 | 2014-12-05 | 抑制劑及其用途 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9446044B2 (zh) |
| EP (1) | EP2744797B1 (zh) |
| JP (1) | JP6017559B2 (zh) |
| KR (1) | KR102006749B1 (zh) |
| CN (1) | CN103797002B (zh) |
| AU (1) | AU2012298510B2 (zh) |
| BR (1) | BR112014003774B1 (zh) |
| CA (1) | CA2848896C (zh) |
| DK (1) | DK2744797T3 (zh) |
| EA (1) | EA026377B1 (zh) |
| ES (1) | ES2551268T3 (zh) |
| HK (1) | HK1198827A1 (zh) |
| IL (1) | IL230917A (zh) |
| PL (1) | PL2744797T3 (zh) |
| PT (1) | PT2744797E (zh) |
| WO (1) | WO2013026806A1 (zh) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014059149A1 (en) * | 2012-10-10 | 2014-04-17 | Felicitex Therapeutics, Inc. | Treatment of cancer by targeting quiescent cancer cells |
| FR3002044A1 (fr) * | 2013-02-08 | 2014-08-15 | Centre Nat Rech Scient | Marqueur dyrk1a pour la maladie d'alzheimer |
| DE102014009011A1 (de) | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Verfahren zum Inhibieren von DYRK1B |
| JP2015107945A (ja) * | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| CA2997556C (en) * | 2015-09-03 | 2020-12-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1a and uses thereof |
| AU2017248807A1 (en) * | 2016-04-15 | 2018-10-25 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
| KR102494174B1 (ko) | 2016-04-15 | 2023-02-02 | 펠리시텍스 쎄라퓨틱스, 인코포레이티드 | 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합 |
| PL3558321T3 (pl) * | 2016-12-23 | 2023-10-23 | Felicitex Therapeutics, Inc. | Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b |
| CN111936490A (zh) | 2017-11-20 | 2020-11-13 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| WO2019136320A1 (en) | 2018-01-05 | 2019-07-11 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| JP2021518413A (ja) | 2018-03-20 | 2021-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
| CN113164476A (zh) * | 2018-09-28 | 2021-07-23 | 代表亚利桑那大学的亚利桑那校董会 | Dyrk1/clk的小分子抑制剂及其用途 |
| AU2019418800A1 (en) * | 2018-12-31 | 2021-07-01 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US20230138851A1 (en) * | 2020-01-30 | 2023-05-04 | Carna Biosciences, Inc. | Novel alkyne derivatives |
| JPWO2022059779A1 (zh) | 2020-09-18 | 2022-03-24 | ||
| WO2022059778A1 (ja) * | 2020-09-18 | 2022-03-24 | カルナバイオサイエンス株式会社 | 環状ウレア誘導体 |
| JPWO2023008472A1 (zh) * | 2021-07-28 | 2023-02-02 | ||
| WO2023008470A1 (ja) * | 2021-07-28 | 2023-02-02 | 住友ファーマ株式会社 | 縮環アミン誘導体 |
| WO2023140846A1 (en) * | 2022-01-20 | 2023-07-27 | Felicitex Therapeutics, Inc. | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| GB0705566D0 (en) * | 2007-03-23 | 2007-05-02 | Univ Dundee | Method of treating learning impairment in down's syndrome subjects |
| FR2943057B1 (fr) * | 2009-03-12 | 2011-06-03 | Centre Nat Rech Scient | DERIVES DE 10-AMINO-1,2,3,4-TETRAHYDROPYRIDO°2,1-a!ISOINDOL-6(10bH)- ONES, LEUR PROCEDE DE PREPARATION ET LEURS UTILISATIONS THERAPEUTIQUES |
| WO2011041655A1 (en) * | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Quinazolin-4-amine derivatives; and methods of use |
-
2012
- 2012-08-17 AU AU2012298510A patent/AU2012298510B2/en active Active
- 2012-08-17 KR KR1020147007325A patent/KR102006749B1/ko active IP Right Grant
- 2012-08-17 ES ES12748470.7T patent/ES2551268T3/es active Active
- 2012-08-17 US US14/238,925 patent/US9446044B2/en active Active
- 2012-08-17 EP EP12748470.7A patent/EP2744797B1/en active Active
- 2012-08-17 PL PL12748470T patent/PL2744797T3/pl unknown
- 2012-08-17 CA CA2848896A patent/CA2848896C/en active Active
- 2012-08-17 JP JP2014525468A patent/JP6017559B2/ja active Active
- 2012-08-17 BR BR112014003774-4A patent/BR112014003774B1/pt active IP Right Grant
- 2012-08-17 DK DK12748470.7T patent/DK2744797T3/en active
- 2012-08-17 WO PCT/EP2012/066151 patent/WO2013026806A1/en active Application Filing
- 2012-08-17 PT PT127484707T patent/PT2744797E/pt unknown
- 2012-08-17 EA EA201400245A patent/EA026377B1/ru not_active IP Right Cessation
- 2012-08-17 CN CN201280040405.7A patent/CN103797002B/zh active Active
-
2014
- 2014-02-11 IL IL230917A patent/IL230917A/en active IP Right Grant
- 2014-12-05 HK HK14112274.6A patent/HK1198827A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140057614A (ko) | 2014-05-13 |
| JP6017559B2 (ja) | 2016-11-02 |
| IL230917A (en) | 2017-02-28 |
| EA201400245A1 (ru) | 2014-07-30 |
| EP2744797B1 (en) | 2015-09-09 |
| US20140275064A1 (en) | 2014-09-18 |
| CN103797002B (zh) | 2017-02-22 |
| WO2013026806A1 (en) | 2013-02-28 |
| BR112014003774A2 (pt) | 2017-03-07 |
| US9446044B2 (en) | 2016-09-20 |
| EP2744797A1 (en) | 2014-06-25 |
| CA2848896C (en) | 2019-10-29 |
| CN103797002A (zh) | 2014-05-14 |
| IL230917A0 (en) | 2014-03-31 |
| KR102006749B1 (ko) | 2019-08-02 |
| JP2014525928A (ja) | 2014-10-02 |
| PT2744797E (pt) | 2015-11-16 |
| BR112014003774B1 (pt) | 2021-12-14 |
| AU2012298510B2 (en) | 2016-10-27 |
| EA026377B1 (ru) | 2017-04-28 |
| AU2012298510A1 (en) | 2014-04-10 |
| DK2744797T3 (en) | 2015-10-19 |
| CA2848896A1 (en) | 2013-02-28 |
| ES2551268T3 (es) | 2015-11-17 |
| PL2744797T3 (pl) | 2016-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100012I1 (hu) | 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók | |
| ZA201704192B (en) | Acc inhibitors and uses thereof | |
| HK1198827A1 (zh) | 抑制劑及其用途 | |
| EP2721031A4 (en) | BROMODOMA INHIBITORS AND ITS USE | |
| EP2705039A4 (en) | BROMODOMAIN INHIBITORS AND USES THEREOF | |
| EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
| EP2663312A4 (en) | IRAQ INHIBITORS AND THEIR USE | |
| IL233051B (en) | Anti-phf-tau antibodies and uses thereof | |
| EP2683693A4 (en) | ROR-GAMMA-T INHIBITORS | |
| EP2696682A4 (en) | MIF-HEMMER AND USES THEREOF | |
| IL229844B (en) | Anti-psgl-1 antibodies and their use | |
| HK1191034A1 (zh) | -羧烷基耳他汀類及其應用 | |
| GB201110783D0 (en) | Methods and uses | |
| GB201116774D0 (en) | Uses and methods | |
| EP2688901A4 (en) | INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10 | |
| EP2693879A4 (en) | MIGRASTATINES AND THEIR USES | |
| GB201108490D0 (en) | Methods and uses | |
| GB201120474D0 (en) | Inhibitors | |
| LT3689878T (lt) | 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai |